Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance Myriad's PrGIS prostate cancer genomic instability score toward clinical trials and potential companion diagnostic use, with AstraZeneca also involved. PrGIS, designed to assess chromosomal instability tied to homologous recombination deficiency in prostate cancer, will be produced by Myriad's MyChoice CDx test, now being advanced for a new prostate cancer indication. SOPHiA GENETICS will build PrGIS into a decentralized companion diagnostic across its network of 1,000+ institutions in 75+ countries, and Myriad plans to present co-authored PrGIS research with AstraZeneca at ESMO Congress 2026.
Key figures
- Drug Name
- PrGIS (prostate cancer-specific genomic instability score)
- Countries covered
- over 75
- Sophia network institutions
- more than 1,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.